Microsoft Word - RadBio_Programme_ParisSept2017_verAug31

1986 / 2063

29
ESTRO
2017
PROTON THERAPY: CLINICAL RESULTS
PRIMARY TUMOR
DRBE
Gy (RBE)
NUMBER
OF
PATIENTS
ofpatients
LOCAL CONTROL REFERENCE
Uveal melanoma 70 in5 Fx 990
1922
99 %at5 yr
96 %at10 yr
Eggeretal. (2001)
Gragoudaset al. (2002)
Skull base
chondrosarcoma ~ 69 202 95 %at10 years Liebsch, N., Personal
communication (2005)
Chordoma ~ 69 132 59 % / 44 %at5 / 10yr Teraharaetal. (1999)
ProstateTIII -TIV
(photons ± protonboost)
67.2 vs. 75.6
(Phase III trial)
202 80 %vs. 92 %at5 yr
60 %vs. 77 %at8 yr Shipley etal. (1995)
Prostate TIa -TII 74 1255
75 % / 73 %biochemical
disease-freesurvival
at 5 / 8yr
Slater et al. (2004)
ProstateTI - TII
(photons ± proton boost) 70.2 vs. 79.2 393 61.4%vs. 80.4%at5 yr Zietman etal. (2005)
Non-small cell lung
cancer. Stage I 73.8 27 86%at2 yr Bush et al. (2004a)
Hepatic cancer 72 (16Fx in 29days)
63 (15Fx in 3
weeks)
162
34
87 %at5 yr
75%at2 yr
Chiba et al. (2005)
Bush et al. (2004b)
Glioblastomamultiforme 90BID in 5weeks 23 34 % / 18 %survival
at 2 / 3yr Fitzeketal. (1999)
Adenocysticcarcinomaof
theparanasal sinus 76  surgery 23 93%at5 years Pommier et al. (2005)
Axial skeleton:
Chondrosarcoma
Chordoma
72.2
74.6
6
14
100%at 5yr
53%at5 yr
Hug etal. (1995)